* pregnancy, nursing, and/or breastfeeding. * study participant has a history of an anaphylactic reaction. * subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug. * has received any prescription or nonprescription over-the-counter (except occasional use of acetaminophen, paracetamol or ibuprofen) medication, topical medications, vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is longer. * subject has a positive urine test for drugs of abuse at the screening visit or admission. * regular consumption of alcohol within 6 months prior to screening or use of illicit substances within 3 months prior to screening. * subject has positive test for sars-cov-2 infection, human immunodeficiency virus (hiv), chronic or active hepatitis b, or active hepatitis c. * donation or loss of blood or plasma within 4 weeks prior to initial dosing. * subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that will affect the subject's ability to participate in the study. * subject has a clinically relevant abnormal ecg; abnormal laboratory values. * subject has hypertension. covid-19 patients: inclusion criteria: * male or female, non-smoker, ≥18 years of age. * participant has active laboratory-confirmed sars-cov-2 infection. * participant must be hospitalized for covid-19 pneumonia. * ability to provide informed consent personally, or by a legally acceptable representative if the participant is unable to do so.

* pregnancy, nursing, and/or breastfeeding. * study participant has a history of an anaphylactic reaction. * subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug. * has received any prescription or nonprescription over-the-counter (except occasional use of acetaminophen, paracetamol or ibuprofen) medication, topical medications, vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is longer. * subject has a positive urine test for drugs of abuse at the screening visit or admission. * regular consumption of alcohol within 6 months prior to screening or use of illicit substances within 3 months prior to screening. * subject has positive test for sars-cov-2 infection, human immunodeficiency virus (hiv), chronic or active hepatitis b, or active hepatitis c. * donation or loss of blood or plasma within 4 weeks prior to initial dosing. * subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that will affect the subject's ability to participate in the study. * subject has a clinically relevant abnormal ecg; abnormal laboratory values. * subject has hypertension. covid-19 patients: inclusion criteria: * male or female, non-smoker, ≥18 years of age. * participant has active laboratory-confirmed sars-cov-2 infection. * participant must be hospitalized for covid-19 pneumonia. * ability to provide informed consent personally, or by a legally acceptable representative if the participant is unable to do so.

- pregnancy, nursing, and/or breastfeeding. - study participant has a history of an anaphylactic reaction. - subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug. - has received any prescription or nonprescription over-the-counter (except occasional use of acetaminophen, paracetamol or ibuprofen) medication, topical medications, vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is longer. - subject has a positive urine test for drugs of abuse at the screening visit or admission. - regular consumption of alcohol within 6 months prior to screening or use of illicit substances within 3 months prior to screening. - subject has positive test for sars-cov-2 infection, human immunodeficiency virus (hiv), chronic or active hepatitis b, or active hepatitis c. - donation or loss of blood or plasma within 4 weeks prior to initial dosing. - subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that will affect the subject's ability to participate in the study. - subject has a clinically relevant abnormal ecg; abnormal laboratory values. - subject has hypertension. covid-19 patients: inclusion criteria: - male or female, non-smoker, ≥18 years of age. - participant has active laboratory-confirmed sars-cov-2 infection. - participant must be hospitalized for covid-19 pneumonia. - ability to provide informed consent personally, or by a legally acceptable representative if the participant is unable to do so.

- pregnancy, nursing, and/or breastfeeding. - study participant has a history of an anaphylactic reaction. - subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug. - has received any prescription or nonprescription over-the-counter (except occasional use of acetaminophen, paracetamol or ibuprofen) medication, topical medications, vitamins, dietary or herbal during the last 14 days or 5 half-lives, whichever is longer. - subject has a positive urine test for drugs of abuse at the screening visit or admission. - regular consumption of alcohol within 6 months prior to screening or use of illicit substances within 3 months prior to screening. - subject has positive test for sars-cov-2 infection, human immunodeficiency virus (hiv), chronic or active hepatitis b, or active hepatitis c. - donation or loss of blood or plasma within 4 weeks prior to initial dosing. - subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy; a history of a psychiatric disorder that will affect the subject's ability to participate in the study. - subject has a clinically relevant abnormal ecg; abnormal laboratory values. - subject has hypertension. covid-19 patients: inclusion criteria: - male or female, non-smoker, ≥18 years of age. - participant has active laboratory-confirmed sars-cov-2 infection. - participant must be hospitalized for covid-19 pneumonia. - ability to provide informed consent personally, or by a legally acceptable representative if the participant is unable to do so.